SELX flagged by Nasdaq for sub-$1 bid; cure period to May 11, 2026
Rhea-AI Filing Summary
Semilux International Ltd. reported a Nasdaq notification that its ordinary shares no longer meet the $1.00 minimum bid requirement under Rule 5550(a)(2), based on closing bids from September 26, 2025 to November 7, 2025.
Under Rule 5810(c)(3)(A), Semilux has 180 calendar days, until May 11, 2026, to regain compliance. If its closing bid price is at least $1.00 for a minimum of 10 consecutive business days within this period, Nasdaq will confirm compliance and close the matter.
If compliance is not regained by that date, the company may qualify for an additional 180 days if it meets other initial listing standards (except bid price) and provides notice of its intention to cure, potentially via a reverse stock split. Semilux is evaluating options and states it intends to regain compliance. The company furnished a press release as Exhibit 99.1.
Positive
- None.
Negative
- None.
Insights
Nasdaq bid-price deficiency disclosed; 180-day cure path available.
Semilux disclosed a notice that its shares fell below the $1.00 minimum bid between Sep 26–Nov 7, 2025. Nasdaq provides until May 11, 2026 to cure by sustaining a closing bid of at least $1.00 for 10 consecutive business days.
The rules also permit a second 180-day window if other initial listing standards are met and the company gives written notice to cure, which may include a reverse stock split. Actual outcomes depend on market trading and any board actions the company undertakes.
The filing lists a clear pathway and timing, but activity will be determined by share price performance and eligibility for an extension. A press release was furnished as Exhibit 99.1.
AI-generated analysis. How Rhea-AI works. Not financial advice.